CL2019001727A1 - Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios. - Google Patents

Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios.

Info

Publication number
CL2019001727A1
CL2019001727A1 CL2019001727A CL2019001727A CL2019001727A1 CL 2019001727 A1 CL2019001727 A1 CL 2019001727A1 CL 2019001727 A CL2019001727 A CL 2019001727A CL 2019001727 A CL2019001727 A CL 2019001727A CL 2019001727 A1 CL2019001727 A1 CL 2019001727A1
Authority
CL
Chile
Prior art keywords
task
respiratory disorders
treatment
pharmaceutical administration
forms containing
Prior art date
Application number
CL2019001727A
Other languages
English (en)
Inventor
Martina Delbeck
Michael Hahn
Udo Albus
Doris Gehring
Björn Rosenstein
Johanna Anlahr
Janine Nicolai
Moritz Beck-Broichsitter
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16205686.5A external-priority patent/EP3338803A1/de
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2019001727A1 publication Critical patent/CL2019001727A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE SOLICITUD SE REFIERE A NUEVOS FORMAS DE ADMINISTRACIÓN FARMACÉUTICA QUE CONTIENEN INHIBIDORES POTENTES Y SELECTIVOS DE LOS CANALES TASK-1 Y / O TASK-3 Y SU USO PARA EL TRATAMIENTO Y / O PREVENCIÓN DE TRASTORNOS RESPIRATORIOS, INCLUYENDO TRASTORNOS RESPIRATORIOS RELACIONADOS CON EL SUEÑO, TALES COMO LA APNEA OBSTRUCTIVA Y LA APNEA CENTRAL DEL SUEÑO Y EL RONQUIDO.
CL2019001727A 2016-12-21 2019-06-20 Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios. CL2019001727A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16205686.5A EP3338803A1 (de) 2016-12-21 2016-12-21 Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
EP17157800 2017-02-24

Publications (1)

Publication Number Publication Date
CL2019001727A1 true CL2019001727A1 (es) 2019-11-29

Family

ID=60812051

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001727A CL2019001727A1 (es) 2016-12-21 2019-06-20 Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios.

Country Status (23)

Country Link
US (1) US20200085734A1 (es)
EP (1) EP3558379A1 (es)
JP (1) JP2020502206A (es)
KR (1) KR20190099211A (es)
CN (1) CN110114091A (es)
AU (1) AU2017379247A1 (es)
BR (1) BR112019012569A2 (es)
CA (1) CA3047428A1 (es)
CL (1) CL2019001727A1 (es)
CO (1) CO2019006654A2 (es)
CR (1) CR20190300A (es)
CU (1) CU20190060A7 (es)
DO (1) DOP2019000171A (es)
EC (1) ECSP19044508A (es)
IL (1) IL267344A (es)
JO (1) JOP20190141A1 (es)
MA (1) MA47069A (es)
MX (1) MX2019007378A (es)
PE (1) PE20191241A1 (es)
PH (1) PH12019501408A1 (es)
TW (1) TW201834654A (es)
UY (1) UY37542A (es)
WO (1) WO2018114503A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180088462A (ko) 2015-12-10 2018-08-03 바이엘 파마 악티엔게젤샤프트 수면-관련 호흡기 장애의 치료를 위한 TASK-1 및 TASK-2 채널의 차단제로서의 2-페닐-3-(피페라지노메틸)이미다조[1,2-a]피리딘 유도체
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
JP7296408B2 (ja) 2018-06-18 2023-06-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤としてのピラゾール誘導体
EA202191480A1 (ru) * 2018-11-27 2021-08-27 Байер Акциенгезельшафт Способ получения фармацевтических лекарственных форм, содержащих ингибиторы task-1- и task-3-каналов, и их применение для терапии нарушений дыхания
TW202108135A (zh) * 2019-05-09 2021-03-01 德商拜耳廠股份有限公司 治療睡眠呼吸中止症之α2-腎上腺素受體亞型C (α-2C)拮抗劑與TASK1/3通道阻斷劑之組合
CA3147105A1 (en) * 2019-05-09 2020-11-12 Bayer Aktiengesellschaft Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
CN1303674A (zh) * 1999-12-02 2001-07-18 山东省医药工业研究所 阿普唑仑鼻喷剂
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CN101636154B (zh) * 2006-04-27 2011-12-14 塞诺菲-安万特德国有限公司 Task-1和task-3离子通道抑制剂
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
US9132243B2 (en) 2010-07-23 2015-09-15 Tannermedico A/S Method of administering a substance to the throat
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
KR20180088462A (ko) * 2015-12-10 2018-08-03 바이엘 파마 악티엔게젤샤프트 수면-관련 호흡기 장애의 치료를 위한 TASK-1 및 TASK-2 채널의 차단제로서의 2-페닐-3-(피페라지노메틸)이미다조[1,2-a]피리딘 유도체

Also Published As

Publication number Publication date
UY37542A (es) 2018-07-31
AU2017379247A1 (en) 2019-06-13
ECSP19044508A (es) 2019-06-30
DOP2019000171A (es) 2019-07-15
US20200085734A1 (en) 2020-03-19
MX2019007378A (es) 2019-09-18
MA47069A (fr) 2021-04-21
IL267344A (en) 2019-08-29
CA3047428A1 (en) 2018-06-28
BR112019012569A2 (pt) 2019-11-26
PH12019501408A1 (en) 2020-02-10
WO2018114503A1 (de) 2018-06-28
CN110114091A (zh) 2019-08-09
CR20190300A (es) 2019-09-23
JP2020502206A (ja) 2020-01-23
TW201834654A (zh) 2018-10-01
CU20190060A7 (es) 2020-02-04
PE20191241A1 (es) 2019-09-16
AU2017379247A8 (en) 2019-07-18
EP3558379A1 (de) 2019-10-30
CO2019006654A2 (es) 2019-06-28
JOP20190141A1 (ar) 2019-06-12
KR20190099211A (ko) 2019-08-26

Similar Documents

Publication Publication Date Title
CL2019001727A1 (es) Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios.
CL2019001726A1 (es) Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios.
ECSP18043573A (es) Derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios relacionados con el sueño
CO2017004649A2 (es) Esteroides neuroactivos para trastornos del snc
IL263709A (en) Methods for the manufacture of cannabinoid prodrugs, pharmaceutical formulations and their use
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
DOP2017000087A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
NI201600021A (es) Inhibidores de rorc2 heterobicicloarilo y sus métodos de uso
BR112018005589A2 (pt) “composto, composição farmaceuticamente aceitável, e, uso de um composto”
MX2016014696A (es) Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.
DOP2021000105A (es) Proceso para la producción de formas farmacéuticas que contienen inhibidores de los canales task–1 y task–3 y su uso para la terapia de trastornos respiratorios
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
AR110417A1 (es) Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor
EA201991538A1 (ru) Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3, и их применение для лечения нарушений дыхания
CL2017000644A1 (es) Compuestos esteroides c-20, composiciones y usos de estos para tratar lesiones cerebrales traumáticas (tbi), incluidas concusiones.
EA201991540A1 (ru) Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3 и их применение для лечения нарушений дыхания
DOP2015000290A (es) Benzoxazoles sustituidos
CL2015003211A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
ES2532749R1 (es) Péptidos bloqueantes de termorreceptores y sus usos